抄録
(1) Among the examinees for hospitalized physical checkup, fewer examinees on. Biloptin (sodium ipodate) medication were found hyperuricemic than those with no history of this medication.
(2) The average serum urate concentration in the examinees for hospitalized physical checkup who were found normal in every checkup parameter was 4.533 mg/dl for the men and 3.610 mg/dl for the women on Biloptin medication, and 5.387 mg/dl for the men and 4.063 mg/dl for the women with no history of this medication.
(3) Among the gout patients admitted for hospitalized physical checkup, those on Biloptin medication included a smaller ratio of hyperuricemic patients than those with no history of this medication.
(4) The examinees for hospitalized physical checkup were medicated orally with 6 tablets of Biloptin, respectively, and 12 hours later the serum urate, serum total bilirubin and blood sugar were determined. Of these findings, the serum urate was decreased, and the serum total bilirubin and blood sugar were elevated, compared with these parameters determined about 1 month later.
(5) Oral medication with Biloptin gives rise to urate diuresis. This medication therefore results in a decrease in serum urate concentration. Biloptin has proved to cause false negative or positive results of some blood biochemical tests, which needs to be carefully considered in designing a laboratory study for the patient on this medication.
